Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Breast Cancer Reports
Erschienen in: Current Breast Cancer Reports 2/2015

01.06.2015 | Risk, Prevention, and Screening (TA Patel, Section Editor)

Vitamin D and Reduction of Breast Cancer Risk

verfasst von: Jennifer K. Lue, Katherine D. Crew

Erschienen in: Current Breast Cancer Reports | Ausgabe 2/2015

Einloggen, um Zugang zu erhalten

Abstract

Vitamin D is not only essential in bone metabolism and calcium homeostasis but also has anticarcinogenic properties in multiple malignancies, including breast cancer. Vitamin D deficiency is a potentially modifiable risk factor that may be easily targeted for breast cancer risk reduction through supplementation. Several epidemiological studies have demonstrated an inverse relationship between dietary intake and blood levels of vitamin D and breast cancer risk; however, the results have been inconsistent. Despite some promising findings, further randomized controlled trials of vitamin D supplements are needed to determine the role of vitamin D in breast cancer prevention.
Literatur
1.
Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10–29.CrossRefPubMed
2.
Jemal A et al. Global cancer statistics. Ca-a Cancer J Clin. 2011;61(2):69–90.CrossRef
3.
Studzinski GP, Moore DC. Sunlight—can it prevent as well as cause cancer? Cancer Res. 1995;55(18):4014–22.PubMed
4.
Gorham ED, Garland FC, Garland CF. Sunlight and breast cancer incidence in the USSR. Int J Epidemiol. 1990;19(4):820–4.CrossRefPubMed
5.
Garland FC et al. Geographic variation in breast cancer mortality in the United States: a hypothesis involving exposure to solar radiation. Prev Med. 1990;19(6):614–22.CrossRefPubMed
6.
Blot WJ, Fraumeni Jr JF, Stone BJ. Geographic patterns of breast cancer in the United States. J Natl Cancer Inst. 1977;59(5):1407–11.PubMed
7.
Welsh J. Vitamin D and breast cancer: insights from animal models. Am J Clin Nutr. 2004;80(6 Suppl):1721S–4S.PubMed
8.
Looker AC et al. Serum 25-hydroxyvitamin D status of the US population: 1988–1994 compared with 2000–2004. Am J Clin Nutr. 2008;88(6):1519–27.CrossRefPubMedCentralPubMed
9.
Wortsman J et al. Decreased bioavailability of vitamin D in obesity. Am J Clin Nutr. 2000;72(3):690–3.PubMed
10.
Giovannucci E. Vitamin D status and cancer incidence and mortality. Adv Exp Med Biol. 2008;624:31–42.CrossRefPubMed
11.
Hewison M et al. 1alpha-Hydroxylase and the action of vitamin D. J Mol Endocrinol. 2000;25(2):141–8.CrossRefPubMed
12.
Schwartz GG et al. Human prostate cells synthesize 1,25-dihydroxyvitamin D3 from 25-hydroxyvitamin D3. Cancer Epidemiol Biomarkers Prev. 1998;7(5):391–5.PubMed
13.
Carlberg C, Dunlop TW. The impact of chromatin organization of vitamin D target genes. Anticancer Res. 2006;26(4A):2637–45.PubMed
14.
Colston KW, Hansen CM. Mechanisms implicated in the growth regulatory effects of vitamin D in breast cancer. Endocr Relat Cancer. 2002;9(1):45–59.CrossRefPubMed
15.•
Feldman D et al. The role of vitamin D in reducing cancer risk and progression. Nat Rev Cancer. 2014;14(5):342–57. A review article that explores the anti-malignant properties and mechanisms of action of vitamin D and its potential role in prevention in multiple cancers.CrossRefPubMed
16.
Abbas S, Linseisen J, Chang-Claude J. Dietary vitamin D and calcium intake and premenopausal breast cancer risk in a German case-control study. Nutr Cancer. 2007;59(1):54–61.CrossRefPubMed
17.
Levi F et al. Dietary intake of selected micronutrients and breast-cancer risk. Int J Cancer. 2001;91(2):260–3.CrossRefPubMed
18.
Potischman N et al. Intake of food groups and associated micronutrients in relation to risk of early-stage breast cancer. Int J Cancer. 1999;82(3):315–21.CrossRefPubMed
19.
Rossi M et al. Vitamin D intake and breast cancer risk: a case-control study in Italy. Ann Oncol. 2009;20(2):374–8.CrossRefPubMed
20.
Simard A, Vobecky J, Vobecky JS. Vitamin D deficiency and cancer of the breast: an unprovocative ecological hypothesis. Can J Public Health. 1991;82(5):300–3.PubMed
21.
Frazier AL et al. Adolescent diet and risk of breast cancer. Cancer Causes Control. 2004;15(1):73–82.
22.
John EM, Vitamin D, et al. Vitamin D and breast cancer risk: the NHANES I Epidemiologic follow-up study, 1971–1975 to 1992. National Health and Nutrition Examination Survey. Cancer Epidemiol Biomarkers Prev. 1999;8(5):399–406.PubMed
23.
Lin J et al. Intakes of calcium and vitamin D and breast cancer risk in women. Arch Intern Med. 2007;167(10):1050–9.CrossRefPubMed
24.
McCullough ML et al. Dairy, calcium, and vitamin D intake and postmenopausal breast cancer risk in the Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiol Biomarkers Prev. 2005;14(12):2898–904.CrossRefPubMed
25.
Robien K, Cutler GJ, Lazovich D. Vitamin D intake and breast cancer risk in postmenopausal women: the Iowa Women’s Health Study. Cancer Causes Control. 2007;18(7):775–82.CrossRefPubMed
26.
Shin MH et al. Intake of dairy products, calcium, and vitamin d and risk of breast cancer. J Natl Cancer Inst. 2002;94(17):1301–11.CrossRefPubMed
27.
Chen P et al. Meta-analysis of vitamin D, calcium and the prevention of breast cancer. Breast Cancer Res Treat. 2010;121(2):469–77.CrossRefPubMed
28.
Frazier AL et al. Adolescent diet and risk of breast cancer. Cancer Causes Control. 2004;15(1):73–82.CrossRefPubMed
29.
Kuper H et al. Prospective study of solar exposure, dietary vitamin D intake, and risk of breast cancer among middle-aged women. Cancer Epidemiol Biomarkers Prev. 2009;18(9):2558–61.CrossRefPubMed
30.
Gonzalez CA, Riboli E. Diet and cancer prevention: contributions from the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Eur J Cancer. 2010;46(14):2555–62.CrossRefPubMed
31.
Edvardsen K et al. Vitamin D-effective solar UV radiation, dietary vitamin D and breast cancer risk. Int J Cancer. 2011;128(6):1425–33.CrossRefPubMed
32.
Abbas S et al. Dietary intake of vitamin D and calcium and breast cancer risk in the European Prospective Investigation into Cancer and Nutrition. Nutr Cancer. 2013;65(2):178–87.CrossRefPubMed
33.•
Kim Y, Je Y. Vitamin D intake, blood 25(OH)D levels, and breast cancer risk or mortality: a meta-analysis. Br J Cancer. 2014;110(11):2772–84. A recent meta-analysis restricted to only prospective cohort studies that explores both the relationship of vitamin D intake and 25-hydroxyvitamin D serum levels with breast cancer risk.CrossRefPubMed
34.
Ross AC et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab. 2011;96(1):53–8.CrossRefPubMedCentralPubMed
35.
World Health Organization. Prevention and management of osteoporosis. World Health Organization Technical Report Series. 2003;921:1–164.
36.
Zerwekh JE. Blood biomarkers of vitamin D status. Am J Clin Nutr. 2008;87(4):1087S–91S.PubMed
37.
38.
Crew KD et al. Association between plasma 25-hydroxyvitamin D and breast cancer risk. Cancer Prev Res (Phila). 2009;2(6):598–604.CrossRef
39.
Garland CF et al. Vitamin D and prevention of breast cancer: pooled analysis. J Steroid Biochem Mol Biol. 2007;103(3–5):708–11.CrossRefPubMed
40.
Abbas S, Chang-Claude J, Linseisen J. Plasma 25-hydroxyvitamin D and premenopausal breast cancer risk in a German case-control study. Int J Cancer. 2009;124(1):250–5.CrossRefPubMed
41.
Abbas S et al. Serum 25-hydroxyvitamin D and risk of post-menopausal breast cancer—results of a large case-control study. Carcinogenesis. 2008;29(1):93–9.CrossRefPubMed
42.
Freedman DM et al. Serum levels of vitamin D metabolites and breast cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol Biomarkers Prev. 2008;17(4):889–94.CrossRefPubMedCentralPubMed
43.
McCullough ML et al. Serum 25-hydroxyvitamin D concentrations and postmenopausal breast cancer risk: a nested case control study in the Cancer Prevention Study-II Nutrition Cohort. Breast Cancer Res. 2009;11(4):R64.CrossRefPubMedCentralPubMed
44.
Rejnmark L et al. Reduced prediagnostic 25-hydroxyvitamin D levels in women with breast cancer: a nested case-control study. Cancer Epidemiol Biomarkers Prev. 2009;18(10):2655–60.CrossRefPubMed
45.
Engel P et al. Serum 25(OH) vitamin D and risk of breast cancer: a nested case-control study from the French E3N cohort. Cancer Epidemiol Biomarkers Prev. 2010;19(9):2341–50.CrossRefPubMed
46.
Wang D et al. Serum 25-hydroxyvitamin D and breast cancer risk: a meta-analysis of prospective studies. Tumour Biol. 2013;34(6):3509–17.CrossRefPubMed
47.
Ordonez-Mena JM et al. Serum 25-hydroxyvitamin d and cancer risk in older adults: results from a large German prospective cohort study. Cancer Epidemiol Biomarkers Prev. 2013;22(5):905–16.CrossRefPubMed
48.
Kuhn T et al. Plasma 25-hydroxyvitamin D and the risk of breast cancer in the European prospective investigation into cancer and nutrition: a nested case-control study. Int J Cancer. 2013;133(7):1689–700.CrossRefPubMed
49.
Mohr SB et al. Serum 25-hydroxyvitamin D and breast cancer in the military: a case-control study utilizing pre-diagnostic serum. Cancer Causes Control. 2013;24(3):495–504.CrossRefPubMed
50.
Scarmo S et al. Circulating levels of 25-hydroxyvitamin D and risk of breast cancer: a nested case-control study. Breast Cancer Res. 2013;15(1):R15.CrossRefPubMedCentralPubMed
51.
Almquist M et al. Serum levels of vitamin D, PTH and calcium and breast cancer risk—a prospective nested case-control study. Int J Cancer. 2010;127(9):2159–68.CrossRefPubMed
52.
Skaaby T et al. Prospective population-based study of the association between serum 25-hydroxyvitamin-D levels and the incidence of specific types of cancer. Cancer Epidemiol Biomarkers Prev. 2014;23(7):1220–9.CrossRefPubMed
53.
Xie SP, Pirianov G, Colston KW. Vitamin D analogues suppress IGF-I signalling and promote apoptosis in breast cancer cells. Eur J Cancer. 1999;35(12):1717–23.CrossRefPubMed
54.
Colston KW et al. Growth inhibition of both MCF-7 and Hs578T human breast cancer cell lines by vitamin D analogues is associated with increased expression of insulin-like growth factor binding protein-3. J Mol Endocrinol. 1998;20(1):157–62.CrossRefPubMed
55.
Bezemer ID et al. C-peptide, IGF-I, sex-steroid hormones and adiposity: a cross-sectional study in healthy women within the European Prospective Investigation into Cancer and Nutrition (EPIC). Cancer Causes Control. 2005;16(5):561–72.CrossRefPubMed
56.
Lukanova A et al. Body mass index, circulating levels of sex-steroid hormones, IGF-I and IGF-binding protein-3: a cross-sectional study in healthy women. Eur J Endocrinol. 2004;150(2):161–71.CrossRefPubMed
57.
Chen WY et al. Associations between polymorphisms in the vitamin D receptor and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2005;14(10):2335–9.CrossRefPubMed
58.
Guy M et al. Vitamin D receptor gene polymorphisms and breast cancer risk. Clin Cancer Res. 2004;10(16):5472–81.CrossRefPubMed
59.
Uitterlinden AG et al. Vitamin D receptor gene polymorphisms in relation to Vitamin D related disease states. J Steroid Biochem Mol Biol. 2004;89–90(1–5):187–93.CrossRefPubMed
60.
Buyru N et al. Vitamin D receptor gene polymorphisms in breast cancer. Exp Mol Med. 2003;35(6):550–5.CrossRefPubMed
61.
Bretherton-Watt D et al. Vitamin D receptor gene polymorphisms are associated with breast cancer risk in a UK Caucasian population. Br J Cancer. 2001;85(2):171–5.CrossRefPubMedCentralPubMed
62.
Ingles SA et al. Vitamin D receptor genotype and breast cancer in Latinas (United States). Cancer Causes Control. 2000;11(1):25–30.CrossRefPubMed
63.
Curran JE et al. Association of A vitamin D receptor polymorphism with sporadic breast cancer development. Int J Cancer. 1999;83(6):723–6.CrossRefPubMed
64.
John EM et al. Sun exposure, vitamin D receptor gene polymorphisms, and breast cancer risk in a multiethnic population. Am J Epidemiol. 2007;166(12):1409–19.CrossRefPubMed
65.
McCullough ML et al. Vitamin D pathway gene polymorphisms, diet, and risk of postmenopausal breast cancer: a nested case-control study. Breast Cancer Res. 2007;9(1):R9.CrossRefPubMedCentralPubMed
66.
Guy M et al. Approaches to evaluating the association of vitamin D receptor gene polymorphisms with breast cancer risk. Recent Results Cancer Res. 2003;164:43–54.CrossRefPubMed
67.
Durrin LK et al. Vitamin D receptor 3'-untranslated region polymorphisms: lack of effect on mRNA stability. Biochim Biophys Acta. 1999;1453(3):311–20.CrossRefPubMed
68.
Whitfield GK et al. Functionally relevant polymorphisms in the human nuclear vitamin D receptor gene. Mol Cell Endocrinol. 2001;177(1–2):145–59.CrossRefPubMed
69.
Trabert B et al. Vitamin D receptor polymorphisms and breast cancer risk in a large population-based case–control study of Caucasian and African-American women. Breast Cancer Res. 2007;9(6):R84.CrossRefPubMedCentralPubMed
70.
Ruggiero M et al. Vitamin D receptor gene polymorphism is associated with metastatic breast cancer. Oncol Res. 1998;10(1):43–6.PubMed
71.•
Afzal S et al. Genetically low vitamin D concentrations and increased mortality: mendelian randomisation analysis in three large cohorts. BMJ. 2014;349:g6330. Recent study using Mendelian randomization to examine the effect of genetically driven vitamin D concentration on cancer mortality.CrossRefPubMedCentralPubMed
72.
73.
74.
Abbas S et al. The Gc2 allele of the vitamin D binding protein is associated with a decreased postmenopausal breast cancer risk, independent of the vitamin D status. Cancer Epidemiol Biomarkers Prev. 2008;17(6):1339–43.CrossRefPubMed
75.
Reimers LL, et al. Vitamin D-related gene polymorphisms, plasma 25-hydroxyvitamin D, and breast cancer risk. Cancer Causes Control. 2015;26(2):187–203.
76.
Jones G. Pharmacokinetics of vitamin D toxicity. Am J Clin Nutr. 2008;88(2):582S–6S.PubMed
77.
Lappe JM et al. Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am J Clin Nutr. 2007;85(6):1586–91.PubMed
78.
79.
Wactawski-Wende J et al. Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med. 2006;354(7):684–96.CrossRefPubMed
80.
Manson JE et al. The VITamin D and OmegA-3 TriaL (VITAL): rationale and design of a large randomized controlled trial of vitamin D and marine omega-3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease. Contemp Clin Trials. 2012;33(1):159–71.CrossRefPubMedCentralPubMed
81.
Boyd NF et al. Mammographic breast density as an intermediate phenotype for breast cancer. Lancet Oncol. 2005;6(10):798–808.CrossRefPubMed
82.
McCormack VA, dos Santos Silva I. Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2006;15(6):1159–69.CrossRefPubMed
83.
Brisson J et al. Synchronized seasonal variations of mammographic breast density and plasma 25-hydroxyvitamin d. Cancer Epidemiol Biomarkers Prev. 2007;16(5):929–33.CrossRefPubMed
84.
Berube S et al. Vitamin D and calcium intakes from food or supplements and mammographic breast density. Cancer Epidemiol Biomarkers Prev. 2005;14(7):1653–9.CrossRefPubMed
85.
Diorio C et al. Influence of insulin-like growth factors on the strength of the relation of vitamin D and calcium intakes to mammographic breast density. Cancer Res. 2006;66(1):588–97.CrossRefPubMed
86.
Colangelo LA et al. A pilot study of vitamin D, calcium, and percent breast density in Hispanic women. Nutr Res. 2006;26(1):11–5.CrossRef
87.
Crew KD et al. Mammographic density and serum 25-hydroxyvitamin D levels. Nutr Metab (Lond). 2014;11:18.CrossRef
88.
Knight JA et al. No association between 25-hydroxyvitamin D and mammographic density. Cancer Epidemiol Biomark Prev. 2006;15(10):1988–92.CrossRef
89.
Green AK et al. Mammographic density, plasma vitamin D levels and risk of breast cancer in postmenopausal women. Int J Cancer. 2010;127(3):667–74.CrossRefPubMedCentralPubMed
90.
Chai W, Maskarinec G, Cooney RV. Serum 25-hydroxyvitamin D levels and mammographic density among premenopausal women in a multiethnic population. Eur J Clin Nutr. 2010;64(6):652–4.CrossRefPubMedCentralPubMed
91.
92.
Crew KD et al. Safety, feasibility, and biomarker effects of high-dose Vitamin D supplementation among women at high risk for breast cancer. Int J Food Sci Nutr Diet. 2015;S1(100):1–9.
Metadaten
Titel
Vitamin D and Reduction of Breast Cancer Risk
verfasst von
Jennifer K. Lue
Katherine D. Crew
Publikationsdatum
01.06.2015
Verlag
Springer US
Erschienen in
Current Breast Cancer Reports / Ausgabe 2/2015
Print ISSN: 1943-4588
Elektronische ISSN: 1943-4596
DOI
https://doi.org/10.1007/s12609-015-0180-5

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

23.04.2024 Medikamente in Schwangerschaft und Stillzeit Nachrichten

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise